ECUR-506 maker DTIL iECURE to present OTC-HOPE trial data at SSIEM
DTIL iECURE plans to present clinical data from its ongoing OTC-HOPE trial of ECUR-506 in neonatal-onset ornithine transcarbamylase deficiency at the SSIEM Annual Symposium.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.